March 13, 2025
| Today’s news and insights for biopharma leaders
The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.
|
The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.
|
Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.
|
Development strategies designed to reduce the unknowns so that cell and gene therapy innovators can develop robust processes efficiently.
|
UPDATED
Vivace Therapeutics brought in $35 million via a Series D round that will support late-stage testing of its “Hippo”-targeting drug for mesothelioma.
|
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.
|
|
It’s time for healthcare sales teams to rethink how they connect with customers. Learn why more sales teams are investing in training that teaches a human-centered approach to sales in this playbook.
|
|
From Our Library
Webinar - on demand
Custom content for Certara
|
Survey Report
Custom content for Tive
|
Playbook
Custom content for Real Chemistry
|
Playbook
Custom content for Hy-Tek Intralogistics
|
| 
